BIOGEN INC. (BIIB)

↓ Download CSV

CIK 0000875045 · Nasdaq · Biological Products, (No Diagnostic Substances)

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, BIOGEN INC. reported revenue of $9.89B, up 2.2% from the prior year. The company was profitable, with a net margin of 13.1%. It held $29.44B in total assets against $11.18B in total liabilities.

Key ratios (FY2025)

13.1%
Net margin
7.1%
Return on equity
+2.2%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$9.89B$9.68B$9.84B$10.17B$10.98B$13.44B$14.38B$13.45B$12.27B$11.45B
Cost of Revenue$2.40B$2.31B$2.53B$2.28B$2.11B$1.81B$1.96B$1.82B$1.63B$1.48B
Gross Profit$11.64B$12.42B$11.64B$10.64B$9.97B
Operating Income$2.84B$4.55B$7.04B$5.89B$5.35B$5.15B
Net Income$1.29B$1.63B$1.16B$3.05B$1.56B$4.00B$5.89B$4.43B$2.54B$3.70B
EPS (Diluted)$8.79$11.18$7.97$20.87$10.40$24.80$31.42$21.58$11.92$16.93
Total Assets$29.44B$28.05B$26.84B$24.55B$23.88B$24.62B$27.23B$25.29B$23.65B$22.88B
Total Liabilities$11.18B$11.33B$12.05B$11.17B$12.92B$13.93B$13.90B$12.26B$11.05B$10.75B
Shareholders' Equity$18.26B$16.72B$14.80B$13.39B$10.96B$10.69B$13.34B$13.03B$12.60B$12.13B
Cash & Equivalents$2.91B$1.22B$1.57B$2.33B
Operating Cash Flow$2.20B$2.88B$1.55B$1.38B$3.64B$4.23B$7.08B$6.19B$4.55B$4.59B
Capital Expenditures$153.80M$153.70M$277.00M$240.30M$258.10M$424.80M$514.50M$770.60M$867.40M$616.10M
Shares Outstanding147.10M145.90M145.60M146.00M149.60M161.30M187.40M205.30M213.00M218.80M